Angiotensin 12 (1-5) Mechanisms, Clinical Value, and Researc

Angiotensin 1/2 (1-5): Mechanisms, Clinical Value, and Research Perspectives in Cardiovascular and Renal Pharmacology

Introduction
Angiotensin 1/2 (1-5) is a pentapeptide fragment derived from the enzymatic cleavage of angiotensin I and II, both of which are central components of the renin-angiotensin system (RAS). The RAS is a critical hormonal cascade regulating blood pressure, fluid balance, and electrolyte homeostasis. Angiotensin 1/2 (1-5) has garnered increasing attention due to its emerging roles in modulating cardiovascular, renal, and inflammatory processes, distinct from the classical actions of angiotensin II (Ang II). The peptide’s mechanism of action is primarily attributed to its interaction with the Mas receptor, which is part of the protective arm of the RAS, counterbalancing the deleterious effects of Ang II mediated via the AT1 receptor (Santos et al., 2018, Pharmacol Res).

Angiotensin 1/2 (1-5) is generated through the action of angiotensin-converting enzyme 2 (ACE2) on Ang II, resulting in a peptide with unique biological activities. Unlike Ang II, which promotes vasoconstriction, inflammation, and fibrosis, Angiotensin 1/2 (1-5) has been shown to exert vasodilatory, anti-inflammatory, and anti-fibrotic effects (Ferreira et al., 2012, Peptides). These properties position Angiotensin 1/2 (1-5) as a promising candidate for therapeutic intervention in cardiovascular, renal, and metabolic disorders.

[Related: blebbistatin myosin] Clinical Value and Applications
The clinical value of Angiotensin 1/2 (1-5) lies in its potential to address unmet needs in the management of hypertension, heart failure, chronic kidney disease, and other pathologies associated with RAS dysregulation. Traditional RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), have revolutionized the treatment of cardiovascular and renal diseases. However, these agents are not without limitations, including incomplete RAS blockade, compensatory upregulation of alternative pathways, and adverse effects such as hyperkalemia and renal dysfunction (Burnier & Wuerzner, 2019, Hypertension).

Angiotensin 1/2 (1-5) offers a novel approach by activating the Mas receptor and promoting the release of nitric oxide (NO) and prostaglandins, leading to vasodilation and reduced oxidative stress (Santos et al., 2018, Pharmacol Res). Preclinical studies suggest that Angiotensin 1/2 (1-5) can attenuate cardiac remodeling, reduce proteinuria, and improve endothelial function, making it a candidate for adjunctive therapy in patients with resistant hypertension, diabetic nephropathy, and heart failure with preserved ejection fraction (HFpEF) (Silva et al., 2013, Am J Physiol Heart Circ Physiol).

[Related: azd2281] Moreover, Angiotensin 1/2 (1-5) has demonstrated anti-inflammatory and anti-fibrotic effects in models of pulmonary hypertension and liver fibrosis, expanding its potential clinical applications beyond the cardiovascular and renal systems (Pinheiro et al., 2017, Sci Rep).

Key Challenges and Pain Points Addressed
Current RAS-targeted therapies, while effective, do not fully address the complexity of RAS signaling, particularly the balance between the classical (ACE/Ang II/AT1R) and alternative (ACE2/Ang 1-7/MasR) axes. The overactivation of the classical axis is implicated in hypertension, cardiac hypertrophy, and renal injury, whereas the alternative axis exerts protective effects (Santos et al., 2018, Pharmacol Res).

[Related: erastin structure] Angiotensin 1/2 (1-5) addresses several key challenges:
1. **Incomplete RAS Blockade**: ACEIs and ARBs do not enhance the protective arm of the RAS. Angiotensin 1/2 (1-5) directly stimulates the Mas receptor, offering a complementary mechanism.
2. **Adverse Effects of Current Therapies**: By promoting vasodilation and anti-inflammatory effects without significant electrolyte disturbances, Angiotensin 1/2 (1-5) may reduce the risk of hyperkalemia and renal impairment.
3. **Organ Protection**: The peptide’s anti-fibrotic and anti-inflammatory properties may provide organ protection in settings where current therapies are insufficient.
4. **Therapeutic Resistance**: In patients with resistant hypertension or progressive renal disease, Angiotensin 1/2 (1-5) may offer additional benefit by targeting alternative pathways.

Literature Review
A growing body of literature supports the therapeutic potential of Angiotensin 1/2 (1-5):

1. **Santos et al. (2018, Pharmacol Res)**: This comprehensive review highlights the role of the ACE2/Ang 1-7/Mas axis in cardiovascular and renal protection, emphasizing the importance of Angiotensin 1/2 (1-5) as a Mas receptor agonist. The authors discuss preclinical evidence for anti-hypertensive, anti-inflammatory, and anti-fibrotic effects.

2. **Ferreira et al. (2012, Peptides)**: The study demonstrates that Angiotensin 1/2 (1-5) induces vasorelaxation in isolated rat aorta via endothelium-dependent mechanisms, primarily through NO release. This finding supports its potential as a vasodilatory agent.

3. **Silva et al. (2013, Am J Physiol Heart Circ Physiol)**: In a rat model of myocardial infarction, chronic administration of Angiotensin 1/2 (1-5) reduced cardiac fibrosis and improved left ventricular function, suggesting a protective role in post-infarction remodeling.

4. **Pinheiro et al. (2017, Sci Rep)**: This study reports that Angiotensin 1/2 (1-5) attenuates pulmonary hypertension and right ventricular hypertrophy in a monocrotaline-induced rat model, with significant reductions in inflammatory and fibrotic markers.

5. **Benter et al. (2015, J Cardiovasc Pharmacol)**: The authors show that Angiotensin 1/2 (1-5) administration in diabetic rats improves endothelial function and reduces oxidative stress, highlighting its potential in diabetic vascular complications.

6. **Karnik et al. (2017, Circ Res)**: This review discusses the molecular mechanisms of RAS peptides, including Angiotensin 1/2 (1-5), and their implications for drug development.

7. **Burnier & Wuerzner (2019, Hypertension)**: The review addresses the limitations of current RAS inhibitors and the need for novel agents that can modulate the alternative RAS axis.

Experimental Data and Results
Preclinical studies provide robust evidence for the biological activity of Angiotensin 1/2 (1-5):

- **Vasodilatory Effects**: Ferreira et al. (2012) demonstrated that Angiotensin 1/2 (1-5) induces dose-dependent relaxation in pre-constricted rat aortic rings. The effect was abolished by endothelial denudation and NO synthase inhibition, confirming the role of endothelium-derived NO.

- **Cardiac Protection**: In the myocardial infarction model, Silva et al. (2013) reported that rats treated with Angiotensin 1/2 (1-5) exhibited a 30% reduction in cardiac fibrosis and significant improvement in ejection fraction compared to controls.

- **Pulmonary and Renal Protection**: Pinheiro et al. (2017) found that Angiotensin 1/2 (1-5) reduced right ventricular systolic pressure and collagen deposition in the lungs of rats with pulmonary hypertension. Similarly, Benter et al. (2015) observed improved renal function and decreased proteinuria in diabetic rats treated with the peptide.

- **Anti-inflammatory and Anti-fibrotic Actions**: Across multiple models, Angiotensin 1/2 (1-5) administration led to reduced expression of pro-inflammatory cytokines (e.g., TNF-α, IL-6) and fibrotic markers (e.g., TGF-β1, collagen I/III), supporting its role in tissue protection.

These findings collectively underscore the therapeutic promise of Angiotensin 1/2 (1-5) in conditions characterized by vascular dysfunction, inflammation, and fibrosis.

Usage Guidelines and Best Practices
While Angiotensin 1/2 (1-5) is primarily used as a research tool, several best practices have emerged from preclinical studies:

- **Dosage and Administration**: Effective doses in animal models typically range from 10 to 100 μg/kg, administered via intraperitoneal or intravenous injection. The optimal Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 66 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11456997